With our industry-leading recombinant antibody expression platform, the process from gene sequence synthesis to antibody purification is completed in just two weeks!
Peptide Research Institute Co., Ltd. offers Biointron's "Recombinant Antibody Production Service." To identify the "optimal" antibody therapeutic, rapid antibody production and evaluation using a high-throughput (HTP) expression platform is necessary. The "Recombinant Antibody Production Service" provides flexibility for rapid large-scale antibody expression using HEK293 or CHO cells at different scales. This allows for significant savings in production time and costs. Please contact us for inquiries. 【Features】 ■ Lead time: 2 weeks ■ High throughput ■ Custom service *For more details, please download the PDF or feel free to contact us.
Inquire About This Product
basic information
【Work Flowchart】 Step 1. Gene Synthesis Step 2. Plasmid Construction and Preparation Step 3. Transient Expression Step 4. Affinity Purification Step 5. Strict Quality Control Step 6. Fast Delivery *For more details, please download the PDF or feel free to contact us.*
Price range
Delivery Time
Applications/Examples of results
For more details, please download the PDF or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
At Peptide Research Institute Co., Ltd., we are enhancing both hardware and software to conduct GMP-compliant peptide synthesis, enabling us to manufacture and sell pharmaceutical raw materials and peptides for clinical research. Since the Protein Research Promotion Association, our predecessor, launched peptide synthesis reagents in 1963, we have contributed to the advancement of life sciences for over half a century, focusing on the research of amino acids, peptides, and sugars. During this time, under the management philosophy of contributing to life sciences, we aim to be a unique company in this field. We strive to provide services that satisfy the needs of our users, with the warm support and valuable information provided by them.
